sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
HIV Drug Market by Medication class [multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FI), entry inhibitors, and HIV integrase stand transfer inhibitors] - Global Opportunity Analysis and Industry Forecast, 2014-2022

HIV Drug Market by Medication class [multi-class combination drugs, nucleoside...

Home / Categories / Healthcare
HIV Drug Market by Medication class [multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FI), entry inhibitors, and HIV integrase stand transfer inhibitors] - Global Opportunity Analysis and Industry Forecast, 2014-2022
HIV Drug Market by Medication...
Report Code
RO1/113/1122

Publish Date
01/Feb/2017

Pages
163
PRICE
$ 1800/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 2350/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 2850/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS
3.4. PRODUCT PIPELINE ANALYSIS
3.5. MARKET DYNAMICS

CHAPTER 4 HIV DRUGS MARKET, BY MEDICATION CLASS

4.1. OVERVIEW
4.2. MULTI-CLASS COMBINATION DRUGS

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast
4.2.4. Atripla: market size and forecast
4.2.5. Complera: market size and forecast
4.2.6. Prezista: market size and forecast
4.2.7. Stribild: market size and forecast
4.2.8. Triumeq: market size and forecast

4.3. NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS)

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. Combivir: market size and forecast
4.3.5. Emtriva: market size and forecast
4.3.6. Epivir: market size and forecast
4.3.7. Epzicom: market size and forecast
4.3.8. Trizivir: market size and forecast
4.3.9. Truvada: market size and forecast
4.3.10. Viread: market size and forecast

4.4. NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS)

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast
4.4.4. Edurant: market size and forecast
4.4.5. Rescriptor: market size and forecast
4.4.6. Sustiva: market size and forecast
4.4.7. Viramune: market size and forecast

4.5. PROTEASE INHIBITORS (PIS)

4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast
4.5.4. Aptivus: market size and forecast
4.5.5. Crixivan: market size and forecast
4.5.6. Kaletra: market size and forecast
4.5.7. Lexiva: market size and forecast
4.5.8. Norvir: market size and forecast
4.5.9. Reyataz: market size and forecast
4.5.10. Viracept: market size and forecast

4.6. FUSION INHIBITORS

4.6.1. Key market trends
4.6.2. Key growth factors and opportunities
4.6.3. Market size and forecast
4.6.4. Fuzeon: market size and forecast

4.7. ENTRY INHIBITORS - CCR5 CO-RECEPTOR ANTAGONIST

4.7.1. Key market trends
4.7.2. Key growth factors and opportunities
4.7.3. Market size and forecast
4.7.4. Selzentry: market size and forecast

4.8. HIV INTEGRASE STRAND TRANSFER INHIBITORS

4.8.1. Key market trends
4.8.2. Key growth factors and opportunities
4.8.3. Market size and forecast
4.8.4. Isentress: market size and forecast
4.8.5. Tivicay: market size and forecast

CHAPTER 5 HIV DRUGS MARKET, BY GEOGRAPHY

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. NORTH AMERICA

5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast

5.3. EUROPE

5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast

5.4. ASIA-PACIFIC

5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast

5.5. LAMEA

5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast

CHAPTER 6 COMPANY PROFILES

6.1. BOEHRINGER INGELHEIM INTERNATIONAL GMBH

6.1.1. Overview
6.1.2. Operating business segments
6.1.3. Business performance
6.1.4. Key strategic moves & developments

6.2. MERCK & CO., INC.

6.2.1. Overview
6.2.2. Operating business segments
6.2.3. Business performance
6.2.4. Key strategic moves & developments

6.3. BRISTOL-MYERS SQUIBB

6.3.1. Overview
6.3.2. Operating business segments
6.3.3. Business performance
6.3.4. Key strategic moves & developments

6.4. GILEAD SCIENCES, INC.

6.4.1. Overview
6.4.2. Operating business segments
6.4.3. Business performance
6.4.4. Key strategic moves & developments

6.5. VIIV HEALTHCARE

6.5.1. Overview
6.5.2. Operating business segments
6.5.3. Business performance
6.5.4. Key strategic moves & developments

6.6. JOHNSON & JOHNSON

6.6.1. Overview
6.6.2. Operating business segments
6.6.3. Business performance
6.6.4. Key Strategic Moves & Developments

6.7. F. HOFFMANN-LA ROCHE LTD

6.7.1. Overview
6.7.2. Operating business segments
6.7.3. Business performance
6.7.4. Key Strategic Moves & Developments

6.8. TEVA PHARMACEUTICAL INDUSTRIES LTD.

6.8.1. Overview
6.8.2. Operating business segments
6.8.3. Business performance
6.8.4. Key Strategic Moves & Developments

6.9. ABBVIE

6.9.1. Overview
6.9.2. Operating business segments
6.9.3. Business performance
6.9.4. Key strategic moves & developments

6.10. CIPLA

6.10.1. Overview
6.10.2. Operating business segments
6.10.3. Business performance
6.10.4. Key Strategic Moves & Developments

LIST OF OTHER PLAYERS IN THE VALUE CHAIN

(These players are not profiled in the report. The same will be included on request)

Daiichi Sankyo
Emcure
Hetero Drugs
Mylan
AstraZeneca

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com